JP5486588B2 - 糖調節のための方法およびシステム - Google Patents
糖調節のための方法およびシステム Download PDFInfo
- Publication number
- JP5486588B2 JP5486588B2 JP2011503199A JP2011503199A JP5486588B2 JP 5486588 B2 JP5486588 B2 JP 5486588B2 JP 2011503199 A JP2011503199 A JP 2011503199A JP 2011503199 A JP2011503199 A JP 2011503199A JP 5486588 B2 JP5486588 B2 JP 5486588B2
- Authority
- JP
- Japan
- Prior art keywords
- nerve
- signal
- time
- electrical signal
- vagus nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 113
- 230000033228 biological regulation Effects 0.000 title claims description 30
- 210000005036 nerve Anatomy 0.000 claims description 204
- 210000001186 vagus nerve Anatomy 0.000 claims description 176
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 99
- 239000008103 glucose Substances 0.000 claims description 99
- 230000000694 effects Effects 0.000 claims description 83
- 238000002560 therapeutic procedure Methods 0.000 claims description 72
- 210000000056 organ Anatomy 0.000 claims description 59
- 238000011084 recovery Methods 0.000 claims description 37
- 238000004891 communication Methods 0.000 claims description 30
- 230000007423 decrease Effects 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 29
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 29
- 210000004185 liver Anatomy 0.000 claims description 28
- 210000000496 pancreas Anatomy 0.000 claims description 28
- 210000001198 duodenum Anatomy 0.000 claims description 23
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 22
- 210000003405 ileum Anatomy 0.000 claims description 20
- 230000004044 response Effects 0.000 claims description 20
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 19
- 230000036961 partial effect Effects 0.000 claims description 19
- 210000002784 stomach Anatomy 0.000 claims description 19
- 238000003860 storage Methods 0.000 claims description 18
- 230000001771 impaired effect Effects 0.000 claims description 17
- 230000009278 visceral effect Effects 0.000 claims description 17
- 230000001515 vagal effect Effects 0.000 claims description 15
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 11
- 208000001280 Prediabetic State Diseases 0.000 claims description 11
- 210000000952 spleen Anatomy 0.000 claims description 5
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 85
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 82
- 230000000903 blocking effect Effects 0.000 description 76
- 230000001537 neural effect Effects 0.000 description 62
- 239000003814 drug Substances 0.000 description 49
- 239000003795 chemical substances by application Substances 0.000 description 48
- 229940079593 drug Drugs 0.000 description 47
- 102000004877 Insulin Human genes 0.000 description 39
- 108090001061 Insulin Proteins 0.000 description 39
- 229940125396 insulin Drugs 0.000 description 39
- 230000002641 glycemic effect Effects 0.000 description 38
- 239000002858 neurotransmitter agent Substances 0.000 description 33
- 102100040918 Pro-glucagon Human genes 0.000 description 32
- 206010012601 diabetes mellitus Diseases 0.000 description 31
- 235000012054 meals Nutrition 0.000 description 29
- 230000004580 weight loss Effects 0.000 description 29
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 26
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 26
- 230000036186 satiety Effects 0.000 description 24
- 235000019627 satiety Nutrition 0.000 description 24
- 235000013305 food Nutrition 0.000 description 23
- 230000008035 nerve activity Effects 0.000 description 23
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 20
- 230000008859 change Effects 0.000 description 20
- 210000003238 esophagus Anatomy 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 16
- 230000002496 gastric effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000003827 upregulation Effects 0.000 description 15
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 14
- 230000008482 dysregulation Effects 0.000 description 14
- 210000000105 enteric nervous system Anatomy 0.000 description 14
- 238000002513 implantation Methods 0.000 description 14
- 235000019577 caloric intake Nutrition 0.000 description 13
- 230000003828 downregulation Effects 0.000 description 13
- 235000003642 hunger Nutrition 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 101800001586 Ghrelin Proteins 0.000 description 11
- 102400000442 Ghrelin-28 Human genes 0.000 description 11
- 208000002705 Glucose Intolerance Diseases 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 11
- 210000001630 jejunum Anatomy 0.000 description 11
- 230000007830 nerve conduction Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 206010022489 Insulin Resistance Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000003914 insulin secretion Effects 0.000 description 10
- 230000037213 diet Effects 0.000 description 9
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 9
- 210000000232 gallbladder Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229940100389 Sulfonylurea Drugs 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000002266 amputation Methods 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 230000030214 innervation Effects 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 229950004994 meglitinide Drugs 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 108010011459 Exenatide Proteins 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 238000000429 assembly Methods 0.000 description 6
- 230000000712 assembly Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229960001519 exenatide Drugs 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019525 fullness Nutrition 0.000 description 5
- 239000003629 gastrointestinal hormone Substances 0.000 description 5
- 230000009229 glucose formation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000003236 esophagogastric junction Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000030136 gastric emptying Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010021518 Impaired gastric emptying Diseases 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000009230 endogenous glucose production Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 208000004104 gestational diabetes Diseases 0.000 description 3
- 230000002039 glucoregulatory effect Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000004007 neuromodulation Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001734 parasympathetic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 206010059186 Early satiety Diseases 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000034991 Hiatal Hernia Diseases 0.000 description 2
- 206010020028 Hiatus hernia Diseases 0.000 description 2
- 208000032984 Intraoperative Complications Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010057765 Procedural complication Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 208000027233 Vagus Nerve injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000021257 carbohydrate digestion Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000000841 delta opiate receptor agonist Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000003020 exocrine pancreas Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000002847 impedance measurement Methods 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000012898 one-sample t-test Methods 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000001202 rhombencephalon Anatomy 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000019553 satiation Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000000393 Ghrelin Receptors Human genes 0.000 description 1
- 108010016122 Ghrelin Receptors Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000004447 accommodation reflex Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000002755 cyclic amp dependent protein kinase inhibitor Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005216 enteric neuron Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229940095885 precose Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012031 short term test Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4257508P | 2008-04-04 | 2008-04-04 | |
| US61/042,575 | 2008-04-04 | ||
| PCT/US2009/039420 WO2009124233A1 (en) | 2008-04-04 | 2009-04-03 | Methods and systems for glucose regulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268765A Division JP5937057B2 (ja) | 2008-04-04 | 2013-12-26 | 糖調節のための方法およびシステム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516177A JP2011516177A (ja) | 2011-05-26 |
| JP5486588B2 true JP5486588B2 (ja) | 2014-05-07 |
Family
ID=40718529
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503199A Expired - Fee Related JP5486588B2 (ja) | 2008-04-04 | 2009-04-03 | 糖調節のための方法およびシステム |
| JP2013268765A Expired - Fee Related JP5937057B2 (ja) | 2008-04-04 | 2013-12-26 | 糖調節のための方法およびシステム |
| JP2015239881A Expired - Fee Related JP6140258B2 (ja) | 2008-04-04 | 2015-12-09 | 糖調節のための方法およびシステム |
| JP2016247977A Withdrawn JP2017051810A (ja) | 2008-04-04 | 2016-12-21 | 糖調節のための方法およびシステム |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268765A Expired - Fee Related JP5937057B2 (ja) | 2008-04-04 | 2013-12-26 | 糖調節のための方法およびシステム |
| JP2015239881A Expired - Fee Related JP6140258B2 (ja) | 2008-04-04 | 2015-12-09 | 糖調節のための方法およびシステム |
| JP2016247977A Withdrawn JP2017051810A (ja) | 2008-04-04 | 2016-12-21 | 糖調節のための方法およびシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US8483830B2 (enExample) |
| EP (2) | EP2300099A1 (enExample) |
| JP (4) | JP5486588B2 (enExample) |
| CN (2) | CN102056645B (enExample) |
| AU (1) | AU2009231601B2 (enExample) |
| HK (1) | HK1217306A1 (enExample) |
| WO (1) | WO2009124233A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| MX2009001114A (es) | 2006-08-09 | 2009-02-10 | Intarcia Therapeutics Inc | Sistemas de suministro osmotico y ensambles de piston. |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| WO2009029614A1 (en) * | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| WO2009124233A1 (en) | 2008-04-04 | 2009-10-08 | Enteromedics, Inc. | Methods and systems for glucose regulation |
| US8868215B2 (en) * | 2008-07-11 | 2014-10-21 | Gep Technology, Inc. | Apparatus and methods for minimally invasive obesity treatment |
| US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
| US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| EP4257178A3 (en) | 2009-04-22 | 2023-10-25 | Nevro Corporation | Spinal cord modulation systems for inducing paresthetic and anesthetic effects |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| DK2462246T3 (da) * | 2009-09-28 | 2017-11-06 | Intarcia Therapeutics Inc | Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| US8825164B2 (en) * | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| WO2013036880A1 (en) | 2011-09-08 | 2013-03-14 | Thacker James R | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
| SG11201402610QA (en) | 2011-12-09 | 2014-10-30 | Metavention Inc | Therapeutic neuromodulation of the hepatic system |
| AU2013202803C1 (en) * | 2012-03-07 | 2016-06-23 | Reshape Lifesciences, Inc. | Devices for regulation of blood pressure and heart rate |
| US20150111918A1 (en) | 2012-03-08 | 2015-04-23 | Medtronic Ardian Luxembourg S.a.r.l | Immune system neuromodulation and associated systems and methods |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US9042596B2 (en) | 2012-06-14 | 2015-05-26 | Medibotics Llc | Willpower watch (TM)—a wearable food consumption monitor |
| US9442100B2 (en) | 2013-12-18 | 2016-09-13 | Medibotics Llc | Caloric intake measuring system using spectroscopic and 3D imaging analysis |
| US9536449B2 (en) | 2013-05-23 | 2017-01-03 | Medibotics Llc | Smart watch and food utensil for monitoring food consumption |
| US9254099B2 (en) | 2013-05-23 | 2016-02-09 | Medibotics Llc | Smart watch and food-imaging member for monitoring food consumption |
| US8504161B1 (en) * | 2012-08-07 | 2013-08-06 | Medtronic, Inc. | Modulate vagal signals to reduce inflammation |
| US10496797B2 (en) | 2012-08-30 | 2019-12-03 | Medtronic Minimed, Inc. | Blood glucose validation for a closed-loop operating mode of an insulin infusion system |
| CA2884997C (en) * | 2012-08-30 | 2020-05-26 | Medtronic Minimed, Inc. | Safeguarding techniques for a closed-loop insulin infusion system |
| US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
| US9364609B2 (en) | 2012-08-30 | 2016-06-14 | Medtronic Minimed, Inc. | Insulin on board compensation for a closed-loop insulin infusion system |
| US9878096B2 (en) | 2012-08-30 | 2018-01-30 | Medtronic Minimed, Inc. | Generation of target glucose values for a closed-loop operating mode of an insulin infusion system |
| US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
| HK1220933A1 (zh) * | 2013-01-28 | 2017-05-19 | Reshape Lifesciences, Inc. | 高效能量神经调制 |
| US9529385B2 (en) | 2013-05-23 | 2016-12-27 | Medibotics Llc | Smart watch and human-to-computer interface for monitoring food consumption |
| WO2014197625A1 (en) | 2013-06-05 | 2014-12-11 | Metavention, Inc. | Modulation of targeted nerve fibers |
| US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
| EP3903876B1 (en) | 2013-09-16 | 2024-10-23 | The Board of Trustees of the Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
| US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
| JP6524339B2 (ja) | 2014-05-18 | 2019-06-05 | ニュースペラ メディカル インク | ミッドフィールドカプラ |
| US20160336813A1 (en) | 2015-05-15 | 2016-11-17 | NeuSpera Medical Inc. | Midfield coupler |
| CN104147699A (zh) * | 2014-07-31 | 2014-11-19 | 李军 | 一种用于治疗2型糖尿病的腹腔神经丛电刺激系统 |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| ES2734194T3 (es) * | 2014-11-03 | 2019-12-04 | Galvani Bioelectronics Ltd | Dispositivo de neuromodulación |
| US20190069949A1 (en) | 2014-12-03 | 2019-03-07 | Metavention, Inc. | Systems and methods for modulatng nerves or other tissue |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| AU2016219951B2 (en) | 2015-02-20 | 2020-04-30 | The Feinstein Institutes For Medical Research | Nerve stimulation for treatment of diseases and disorders |
| WO2016141184A1 (en) * | 2015-03-03 | 2016-09-09 | Georgia Tech Research Corporation | Glucose regulation via electrical stimulation of nerves innervating the liver |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| JP2017000437A (ja) * | 2015-06-10 | 2017-01-05 | オリンパス株式会社 | 心筋再生装置 |
| US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| ES2876148T3 (es) | 2016-01-25 | 2021-11-12 | Nevro Corp | Tratamiento de la insuficiencia cardíaca congestiva con estimulación eléctrica y sistemas y métodos asociados |
| WO2017197272A1 (en) | 2016-05-13 | 2017-11-16 | Georgia Tech Research Corporation | Systems, methods, and devices for neuromodulation |
| MA53353A (fr) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| US9955882B2 (en) | 2016-08-31 | 2018-05-01 | Medtronic Xomed, Inc. | System to monitor neural integrity |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
| EP3612083B8 (en) | 2017-04-20 | 2022-12-28 | The Feinstein Institutes for Medical Research | Systems and methods for real-time monitoring of physiological biomarkers through nerve signals and uses thereof |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| EP3762090A1 (en) * | 2018-03-09 | 2021-01-13 | General Electric Company | Ultrasound neuromodulation techniques |
| IL277949B2 (en) * | 2018-04-12 | 2025-02-01 | Reshape Lifesciences Inc | Simultaneous multi-site vagus nerve neuromodulation for a system and methods for improved glycemic control |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
| US11623091B2 (en) * | 2019-02-13 | 2023-04-11 | Avent, Inc. | Portable electrical stimulation system and method |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| CN110064130A (zh) * | 2019-04-17 | 2019-07-30 | 上海黎欧生物科技有限公司 | 一种胆囊起搏器 |
| WO2020214982A1 (en) * | 2019-04-18 | 2020-10-22 | Reshape Lifesciences, Inc. | Methods and systems for neural regulation |
| IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| WO2022212646A1 (en) * | 2021-04-01 | 2022-10-06 | Reshape Lifesciences, Inc. | Neuromodulation system and methods for the treatment of a hypoglycemic state |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| US20230355975A1 (en) * | 2022-05-05 | 2023-11-09 | Medtronic, Inc. | Neuromodulation techniques to create a nerve blockage with a combination stimulation/block therapy for glycemic control |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231988A (en) * | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
| US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
| US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
| WO2004112563A2 (en) | 2003-06-20 | 2004-12-29 | Metacure N.V., | Gastrointestinal methods and apparatus for use in treating disorders |
| US20040249421A1 (en) | 2000-09-13 | 2004-12-09 | Impulse Dynamics Nv | Blood glucose level control |
| IL129032A (en) | 1999-03-17 | 2006-12-31 | Moshe Dudai | Stomach strap |
| US6885888B2 (en) | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
| EP1305046A2 (en) * | 2000-07-20 | 2003-05-02 | Bristol-Myers Squibb Company | Regulators of ppardelta (beta) and their use in the treatment of obesity and insulin resistance |
| US6832114B1 (en) | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
| US7167751B1 (en) | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
| US7702394B2 (en) | 2001-05-01 | 2010-04-20 | Intrapace, Inc. | Responsive gastric stimulator |
| US6928320B2 (en) | 2001-05-17 | 2005-08-09 | Medtronic, Inc. | Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated |
| US20060116736A1 (en) | 2001-07-23 | 2006-06-01 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity |
| US7689276B2 (en) | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
| US7702386B2 (en) | 2002-03-22 | 2010-04-20 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes |
| US7239912B2 (en) | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
| US7689277B2 (en) * | 2002-03-22 | 2010-03-30 | Leptos Biomedical, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
| WO2004033034A1 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for neural stimulation and controlled drug delivery |
| US7167750B2 (en) | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
| US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
| US7844338B2 (en) | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
| US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
| US7620454B2 (en) | 2003-05-19 | 2009-11-17 | Medtronic, Inc. | Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof |
| US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
| JP4960700B2 (ja) | 2003-07-21 | 2012-06-27 | メタキュアー リミティド | 疾患を治療し、血糖を制御する際に使用するための胃腸処置方法および装置 |
| US20070060971A1 (en) * | 2003-07-21 | 2007-03-15 | Ofer Glasberg | Hepatic device for treatment or glucose detection |
| US7711432B2 (en) * | 2004-07-26 | 2010-05-04 | Advanced Neuromodulation Systems, Inc. | Stimulation system and method for treating a neurological disorder |
| US8214047B2 (en) | 2004-09-27 | 2012-07-03 | Advanced Neuromodulation Systems, Inc. | Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions |
| US7613520B2 (en) | 2004-10-21 | 2009-11-03 | Advanced Neuromodulation Systems, Inc. | Spinal cord stimulation to treat auditory dysfunction |
| US20060122099A1 (en) * | 2004-12-08 | 2006-06-08 | Aoki Thomas T | Method for infusing insulin to a subject to improve impaired total body tissue glucose processing |
| AU2005323463B2 (en) * | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
| US8260426B2 (en) | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
| US9339190B2 (en) | 2005-02-17 | 2016-05-17 | Metacure Limited | Charger with data transfer capabilities |
| US7561923B2 (en) | 2005-05-09 | 2009-07-14 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling autonomic balance using neural stimulation |
| US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
| US20070027484A1 (en) * | 2005-07-28 | 2007-02-01 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a pancreatic disorder |
| US7620455B2 (en) | 2005-10-25 | 2009-11-17 | Cyberonics, Inc. | Cranial nerve stimulation to treat eating disorders |
| EP1948301B8 (en) * | 2005-11-10 | 2014-03-12 | ElectroCore LLC | Electrical stimulation treatment of bronchial constriction |
| US8041428B2 (en) | 2006-02-10 | 2011-10-18 | Electrocore Llc | Electrical stimulation treatment of hypotension |
| CA2637851C (en) * | 2006-01-23 | 2016-01-05 | Rehabtronics Inc. | Method of routing electrical current to bodily tissues via implanted passive conductors |
| CA2637787A1 (en) | 2006-02-03 | 2007-08-16 | Synecor, Llc | Intravascular device for neuromodulation |
| US7711430B2 (en) | 2006-02-10 | 2010-05-04 | Electrocore Llc | Methods and apparatus for treating anaphylaxis using electrical modulation |
| US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
| WO2007137026A2 (en) | 2006-05-18 | 2007-11-29 | Cedars-Sinai Medical Center | Electrical stimulation of the lower esophageal sphincter |
| US8634930B2 (en) | 2006-06-30 | 2014-01-21 | Cardiac Pacemakers, Inc. | System for providing diabetic therapy |
| US8068918B2 (en) | 2007-03-09 | 2011-11-29 | Enteromedics Inc. | Remote monitoring and control of implantable devices |
| US20080281365A1 (en) | 2007-05-09 | 2008-11-13 | Tweden Katherine S | Neural signal duty cycle |
| US8532787B2 (en) | 2007-05-31 | 2013-09-10 | Enteromedics Inc. | Implantable therapy system having multiple operating modes |
| US20080300645A1 (en) | 2007-05-31 | 2008-12-04 | Pacesetter, Inc. | Treatment of cardiomyopathy, heart failure and cardiac ischemia using stimulation induced secretion of glp-1 |
| US20080300648A1 (en) | 2007-05-31 | 2008-12-04 | Pacesetter, Inc. | Treatment of cardiomyopathy, heart failure and cardiac ischemia using stimulation induced secretion of glp-1 |
| US20080300646A1 (en) | 2007-05-31 | 2008-12-04 | Pacesetter, Inc. | Treatment of cardiomyopathy, heart failure and cardiac ischemia using stimulation induced secretion of glp-1 |
| US20080300647A1 (en) | 2007-05-31 | 2008-12-04 | Pacesetter, Inc. | Treatment of cardiomyopathy, heart failure and cardiac ischemia using stimulation induced secretion of glp-1 |
| EP2254462B1 (en) | 2007-11-12 | 2015-05-20 | Daniel J. Dilorenzo | Apparatus for programming of autonomic neuromodulation for the treatment of obesity |
| WO2009102969A1 (en) * | 2008-02-14 | 2009-08-20 | Enteromedics, Inc. | Treatment of excess weight by neural downregulation in combination with compositions |
| WO2009124233A1 (en) | 2008-04-04 | 2009-10-08 | Enteromedics, Inc. | Methods and systems for glucose regulation |
| US20090254133A1 (en) | 2008-04-07 | 2009-10-08 | Wendell Keith F | Method for treatment of diabetes by electrostimulatioin |
| US8204603B2 (en) | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
| US20090275997A1 (en) | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
| EP2334374A4 (en) | 2008-08-26 | 2011-12-28 | Janssen Biotech Inc | STIMULATING THE RELEASE OF A SATIETY HORMONE |
| WO2010128167A1 (en) | 2009-05-08 | 2010-11-11 | Universite Libre De Bruxelles | Gastrointestinal device |
| US20120259389A1 (en) | 2009-09-21 | 2012-10-11 | Warren Starkebaum | Treatment of postprandial hyperglycemia by gastric electrical stimulation |
| WO2011092710A2 (en) | 2010-02-01 | 2011-08-04 | Metacure Limited | Gastrointestinal electrical therapy |
| CA2800889C (en) | 2010-05-27 | 2018-12-04 | Ndi Medical, Llc | Waveform shapes for treating neurological disorders optimized for energy efficiency |
| US8620450B2 (en) | 2010-07-19 | 2013-12-31 | Cardiac Pacemakers, Inc. | Minimally invasive lead system for vagus nerve stimulation |
| US20130184775A1 (en) | 2010-10-01 | 2013-07-18 | Indiana University Research & Technology Corporation | Long term vagal nerve stimulation for therapeutic and diagnostic treatment |
| WO2012060874A2 (en) | 2010-11-01 | 2012-05-10 | Udaya Sankar Devanaboyina | Methods for diagnosis and treatment of disorders of the gastrointestinal tract. and apparatus for use therewith |
| WO2012061608A2 (en) | 2010-11-03 | 2012-05-10 | The Cleveland Clinic Foundation | Apparatus for energy efficient stimulation |
| MX2013006546A (es) | 2010-12-17 | 2013-09-05 | Neural Diabetes Llc | Metodo, sistema y aparato para controlar la funcion de celulas beta pancreaticas para mejorar la homeostasis de glucosa y la produccion de insulina. |
-
2009
- 2009-04-03 WO PCT/US2009/039420 patent/WO2009124233A1/en not_active Ceased
- 2009-04-03 AU AU2009231601A patent/AU2009231601B2/en not_active Ceased
- 2009-04-03 EP EP09728652A patent/EP2300099A1/en not_active Withdrawn
- 2009-04-03 CN CN200980120949.2A patent/CN102056645B/zh not_active Expired - Fee Related
- 2009-04-03 EP EP15195939.2A patent/EP3047874B1/en active Active
- 2009-04-03 US US12/417,918 patent/US8483830B2/en active Active
- 2009-04-03 CN CN201510277948.6A patent/CN105031811B/zh not_active Expired - Fee Related
- 2009-04-03 JP JP2011503199A patent/JP5486588B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-20 US US13/681,581 patent/US9333340B2/en active Active - Reinstated
-
2013
- 2013-12-26 JP JP2013268765A patent/JP5937057B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-09 JP JP2015239881A patent/JP6140258B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-14 US US15/098,704 patent/US9974955B2/en active Active
- 2016-05-10 HK HK16105291.7A patent/HK1217306A1/zh unknown
- 2016-12-21 JP JP2016247977A patent/JP2017051810A/ja not_active Withdrawn
-
2018
- 2018-05-21 US US15/984,926 patent/US10722714B2/en active Active
-
2020
- 2020-07-27 US US16/939,754 patent/US20210046313A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105031811A (zh) | 2015-11-11 |
| JP2014087681A (ja) | 2014-05-15 |
| JP6140258B2 (ja) | 2017-05-31 |
| EP3047874B1 (en) | 2022-03-09 |
| AU2009231601A2 (en) | 2010-11-04 |
| US8483830B2 (en) | 2013-07-09 |
| US20170021174A1 (en) | 2017-01-26 |
| JP5937057B2 (ja) | 2016-06-22 |
| WO2009124233A1 (en) | 2009-10-08 |
| US9333340B2 (en) | 2016-05-10 |
| JP2016064151A (ja) | 2016-04-28 |
| JP2017051810A (ja) | 2017-03-16 |
| HK1217306A1 (zh) | 2017-01-06 |
| JP2011516177A (ja) | 2011-05-26 |
| US9974955B2 (en) | 2018-05-22 |
| CN105031811B (zh) | 2017-09-08 |
| CN102056645B (zh) | 2015-07-01 |
| AU2009231601A1 (en) | 2009-10-08 |
| AU2009231601B2 (en) | 2014-02-27 |
| US20210046313A1 (en) | 2021-02-18 |
| EP3047874A1 (en) | 2016-07-27 |
| US10722714B2 (en) | 2020-07-28 |
| US20190022393A1 (en) | 2019-01-24 |
| CN102056645A (zh) | 2011-05-11 |
| US20130079745A1 (en) | 2013-03-28 |
| US20090254143A1 (en) | 2009-10-08 |
| EP2300099A1 (en) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6140258B2 (ja) | 糖調節のための方法およびシステム | |
| US20250295920A1 (en) | Simultaneous multi-site vagus nerve neuromodulation for improved glycemic control system and methods | |
| JP2014028314A (ja) | 血圧および心拍数の調節のためのシステム | |
| CN105268100A (zh) | 神经调节设备和方法 | |
| AU2016201492B2 (en) | Methods and systems for glucose regulation | |
| AU2014202313B2 (en) | Methods and systems for glucose regulation | |
| HK1227346A1 (en) | Systems for glucose regulation and methods of making such systems | |
| HK1227346B (en) | Systems for glucose regulation and methods of making such systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5486588 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |